二甲双胍和拜糖平治疗糖耐量减低临床研究

目的观察二甲双胍和拜糖平治疗葡萄糖耐量减低(IGT)的疗效。方法于2006年1月～2007年6月对24例年龄在32～56岁的初诊IGT(空腹血浆葡萄糖<7.0mmol/L、7.8mmol/L≤葡萄糖负荷后2h血浆葡萄糖<11.1mmol/L)患者,经生活方式干预1个月后,仍达到或超过以上最低基线者,随机分为两组,分别给予二甲双胍1000mg/d或拜糖平150mg/d,疗程3个月。观察治疗前后体重、血压、心率、体重指数、葡萄糖耐量试验、血胰岛素和血脂水平等的变化。结果两组患者治疗后血糖、胰岛素水平均明显降低,体重略有减轻,胰岛素敏感指数略有升高。结论二甲双胍和拜糖平治疗IGT疗效可靠,并改善胰岛素抵抗、减轻体重。

Clinical study of metformin and acarbose therapy in impaired glucose tolerance

Objective The efficacy of metformin and Acarbose therapy in impaired glucose tolerance (IGT).Methods Twenty-four cases of IGT were diveded into 2 groups,metformin treatment group was given metformin 1.0g/day and Acarbose treatment group was given Acarbose 0. 15g/day for 3 months. The changes of body weight,blood pressure,lipid profiles,plasma glucose,oral glucose tolerance test and insulin level were analyzed.Results Two group patients plasma glucose,insulin level decreased after treatment.Conlusion The efficacy is superior metformin or Acarbose therapy in IGT,and improve the insulin resistance,reduce weight.